Surgery of enlarging lesions after stereotactic radiosurgery for brain metastases in patients with non-small cell lung cancer with oncogenic driver mutations frequently reveals radiation necrosis: case series and review

IF 2.2 4区 医学 Q4 IMMUNOLOGY
Apmis Pub Date : 2024-03-11 DOI:10.1111/apm.13402
Fang Zhou, Leilei Jiang, Xuankai Sun, Zhen Wang, Jialin Feng, Ming Liu, Zhao Ma
{"title":"Surgery of enlarging lesions after stereotactic radiosurgery for brain metastases in patients with non-small cell lung cancer with oncogenic driver mutations frequently reveals radiation necrosis: case series and review","authors":"Fang Zhou,&nbsp;Leilei Jiang,&nbsp;Xuankai Sun,&nbsp;Zhen Wang,&nbsp;Jialin Feng,&nbsp;Ming Liu,&nbsp;Zhao Ma","doi":"10.1111/apm.13402","DOIUrl":null,"url":null,"abstract":"<p>In brain metastases, radiation necrosis (RN) is a complication that arises after single or multiple fractionated stereotactic radiosurgery (SRS/FSRS), which is challenging to distinguish from local recurrence (LR). Studies have shown increased RN incidence rates in non-small cell lung cancer (NSCLC) patients with oncogenic driver mutations (ODMs) or receiving tyrosine kinase inhibitors (TKIs). This study investigated enlarging brain lesions following SRS/FSRS, for which additional surgeries were performed to distinguish between RN and LR. We investigated seven NSCLC patients with ODMs undergoing SRS/FSRS for BM and undergoing surgery for suspicion of LR on MRI imaging. Descriptive statistics were performed. Among the seven patients, six were EGFR+, while one was ALK+. The median irradiation dose was 30 Gy (range, 20–35 Gy). The median time to develop RN after SRS/FSRS was 11.1 months (range: 6.3–31.2 months). Moreover, gradually enlarging lesions were found in all patients after 6 months post-SRS/FSR. Brain radiation necrosis was pathologically confirmed in all the patients. RN should be suspected in NSCLC patients when lesions keep enlarging after 6 months post-SRS/FSRS, especially for patients with ODMs and receiving TKIs. Further, this case series indicates that further dose reduction might be necessary to avoid RN for such patients.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 6","pages":"375-381"},"PeriodicalIF":2.2000,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Apmis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apm.13402","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In brain metastases, radiation necrosis (RN) is a complication that arises after single or multiple fractionated stereotactic radiosurgery (SRS/FSRS), which is challenging to distinguish from local recurrence (LR). Studies have shown increased RN incidence rates in non-small cell lung cancer (NSCLC) patients with oncogenic driver mutations (ODMs) or receiving tyrosine kinase inhibitors (TKIs). This study investigated enlarging brain lesions following SRS/FSRS, for which additional surgeries were performed to distinguish between RN and LR. We investigated seven NSCLC patients with ODMs undergoing SRS/FSRS for BM and undergoing surgery for suspicion of LR on MRI imaging. Descriptive statistics were performed. Among the seven patients, six were EGFR+, while one was ALK+. The median irradiation dose was 30 Gy (range, 20–35 Gy). The median time to develop RN after SRS/FSRS was 11.1 months (range: 6.3–31.2 months). Moreover, gradually enlarging lesions were found in all patients after 6 months post-SRS/FSR. Brain radiation necrosis was pathologically confirmed in all the patients. RN should be suspected in NSCLC patients when lesions keep enlarging after 6 months post-SRS/FSRS, especially for patients with ODMs and receiving TKIs. Further, this case series indicates that further dose reduction might be necessary to avoid RN for such patients.

具有致癌驱动基因突变的非小细胞肺癌患者在接受立体定向放射外科手术治疗脑转移瘤后,对扩大病灶进行的手术经常会发现辐射坏死:病例系列和综述。
在脑转移瘤中,放射坏死(RN)是单次或多次分次立体定向放射手术(SRS/FSRS)后出现的一种并发症,很难与局部复发(LR)区分开来。研究表明,在有致癌驱动基因突变(ODMs)或接受酪氨酸激酶抑制剂(TKIs)治疗的非小细胞肺癌(NSCLC)患者中,RN发生率增加。本研究调查了 SRS/FSRS 后扩大的脑部病变,并对其进行了额外手术以区分 RN 和 LR。我们调查了七名因BM而接受SRS/FSRS治疗并因MRI成像怀疑LR而接受手术治疗的患有ODM的NSCLC患者。我们进行了描述性统计。七名患者中,六名为表皮生长因子受体(EGFR)+,一名为ALK+。中位照射剂量为30 Gy(范围为20-35 Gy)。SRS/FSRS后出现RN的中位时间为11.1个月(范围:6.3-31.2个月)。此外,所有患者在接受 SRS/FSR 治疗 6 个月后均发现病灶逐渐扩大。所有患者的脑放射坏死均经病理证实。如果NSCLC患者在SRS/FSRS术后6个月后病灶继续扩大,尤其是患有ODMs并接受TKIs治疗的患者,则应怀疑RN。此外,本系列病例表明,为避免此类患者出现 RN,可能需要进一步减少剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Apmis
Apmis 医学-病理学
CiteScore
5.20
自引率
0.00%
发文量
91
审稿时长
2 months
期刊介绍: APMIS, formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica, has been published since 1924 by the Scandinavian Societies for Medical Microbiology and Pathology as a non-profit-making scientific journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信